Rapport Therapeutics Inc
NASDAQ:RAPP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
US |
|
D
|
Demant A/S
SWB:WDH1
|
DK |
|
S
|
Siminn hf
ICEX:SIMINN
|
IS |
|
Starwood Property Trust Inc
NYSE:STWD
|
US |
|
AIA Group Ltd
HKEX:1299
|
HK |
|
B
|
Bceg Environmental Remediation Co Ltd
SZSE:300958
|
CN |
|
Newegg Commerce Inc
NASDAQ:NEGG
|
US |
|
V
|
VMware Inc
XETRA:BZF1
|
US |
|
Banco BTG Pactual SA
BOVESPA:BPAC5
|
BR |
|
Wiz Co Participacoes e Corretagem de Seguros SA
BOVESPA:WIZC3
|
BR |
|
AES Brasil Energia SA
BOVESPA:AESB3
|
BR |
Rapport Therapeutics Inc
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The firm focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. The company advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The firm focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. The company advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
